Show simple item record

dc.contributor.authorGuðmundur I. Bergþórsson
dc.contributor.authorÞórólfur Matthíasson
dc.contributor.authorÞórólfur Guðnason
dc.contributor.authorHaraldur Briemen
dc.date.accessioned2006-04-28T14:59:13Z
dc.date.available2006-04-28T14:59:13Z
dc.date.issued2004-05-01T14:59:13Z
dc.identifier.citationLæknablaðið 2004;90(5):379-83en
dc.identifier.issn0023-7213
dc.identifier.pmid16819032
dc.identifier.urihttp://hdl.handle.net/2336/2046
dc.descriptionNeðst á síðunni er hægt að nálgast greinina í heild sinni með því að smella á hlekkinn View/Openen
dc.description.abstractMeningococci C are bacteria that can cause meningitis and severe bacteremia. In Iceland 8-15 cases of meningococcal disease can be expected annually. The case fatality ratio is approximately 10%. After the approval of the Icelandic government The State Epidemiologist started a vaccination campaign for all individuals from 6 months to 19 years of age in the country. The purpose of this investigation is to evaluate the cost effectiveness of the vaccination programme. The cost effectiveness is made from the viewpoint of the Icelandic state. The cost per year saved is used as a marker for success. The cost effectiveness analysis reveals that the cost per case avoided is 618.000 Icelandic kronas and the cost per life year saved is 101.000 Icelandic kronas. In comparison the cost per case avoided is 2.481.334 Icelandic kronas and the cost per life saved is 857.483 Icelandic kronas in England and Wales. We conclude that vaccination against meningococci C is very cost effective but lower cost in Iceland can mainly be explained by lower cost of distributing and administering the vaccine to the vaccinees in Iceland compared to England and Wales.
dc.language.isoisen
dc.publisherLæknafélag Íslands, Læknafélag Reykjavíkuren
dc.relation.urlhttp://www.laeknabladid.isen
dc.subjectMeningókokkar Cen
dc.subjectÓnæmisaðgerðiren
dc.subjectBólusetningaren
dc.subjectHeilahimnubólgaen
dc.subjectHeilsuhagfræðien
dc.subject.classificationLBL12en
dc.subject.classificationFræðigreinaren
dc.subject.meshMeningococcal Diseaseen
dc.subject.meshCost-effectiveness analysisen
dc.titleKostnaðarhagkvæmnisgreining á bólusetningu gegn meningókokkum C á Íslandien
dc.title.alternativeCost-effectiveness analysis on meningococcal serogroup C vaccinationen
dc.typeArticleen
dc.identifier.journalLæknablaðiðis
dc.format.digYES
refterms.dateFOA2018-09-12T12:13:24Z
html.description.abstractMeningococci C are bacteria that can cause meningitis and severe bacteremia. In Iceland 8-15 cases of meningococcal disease can be expected annually. The case fatality ratio is approximately 10%. After the approval of the Icelandic government The State Epidemiologist started a vaccination campaign for all individuals from 6 months to 19 years of age in the country. The purpose of this investigation is to evaluate the cost effectiveness of the vaccination programme. The cost effectiveness is made from the viewpoint of the Icelandic state. The cost per year saved is used as a marker for success. The cost effectiveness analysis reveals that the cost per case avoided is 618.000 Icelandic kronas and the cost per life year saved is 101.000 Icelandic kronas. In comparison the cost per case avoided is 2.481.334 Icelandic kronas and the cost per life saved is 857.483 Icelandic kronas in England and Wales. We conclude that vaccination against meningococci C is very cost effective but lower cost in Iceland can mainly be explained by lower cost of distributing and administering the vaccine to the vaccinees in Iceland compared to England and Wales.


Files in this item

Thumbnail
Name:
blankfile.xxxx
Size:
0bytes
Format:
Text file
Description:
blank file placeholder
Thumbnail
Name:
L2004-05-90-F1.pdf
Size:
151.6Kb
Format:
PDF
Description:
Allur texti - Full Text

This item appears in the following Collection(s)

Show simple item record